Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
基本信息
- 批准号:9175121
- 负责人:
- 金额:$ 13.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Our long-term goal is to develop non-toxic, low-cost and efficacious herbal modalities from Korean Angelica gigas Nakai (AGN) for the prevention of prostate carcinogenesis and metastasis in men. We have shown in preclinical models significant prostate cancer growth-inhibitory and chemopreventive effects of AGN ethanol extracts without any observable toxicity to the host mice. Nevertheless, a lack of mechanistic knowledge of active chemicals and in vivo molecular targets is a significant roadblock to translating the preventive benefits to men. The objective for the current application is to generate mechanistic knowledge of (1) the active chemicals and (2) cellular and molecular targets in two independent and complementary prostate cancer models. We hypothesize that AGN extract exerts in vivo efficacy (a) mainly through pyranocoumarin compounds and their metabolite; (b) by affecting critical cellular processes and molecular targets, which can be effectively profiled through a systems-biology approach. We plan to test these hypotheses by pursuing three specific aims: Aim 1. Establish the chemical mediator role of the pyranocoumarins by comparing the efficacy of purified compounds with AGN extract and pyranocoumarin-knockout (KO) extract to inhibit human prostate cancer growth and metastasis in xenograft models in immunodeficient mice. Aim 2. Validate their mediator role for chemopreventive efficacy against primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model by comparing them with AGN extract and KO extract. Aim 3. Determine key cellular indices and molecular biomarkers of in vivo efficacy including angiogenesis, apoptosis, cell proliferation and invasiveness by focused analyses and identify molecular targets with systems-biology approaches, using suitable tissues from the first two aims. The work proposed in Aims 1 and 2 is expected to critically assess the role of pyranocoumarins and metabolites as chemical mediators for the inhibitory efficacy of AGN extract against prostate primary carcinogenesis and metastasis, and establish their long-term safety profiles in mice models. Such results are expected to positively impact future focused R&D efforts and quality control for AGN herbal products. Aim 3 results are expected to identify candidate in vivo molecular targets and cellular processes. Better knowledge of the active chemicals and their molecular targets in model systems enables further mechanistic studies and rational planning for clinical translation in men. Furthermore, the efficacy and mechanisms are likely exportable to the prevention of cancers of other organ sites by AGN extracts. The research proposed is innovative, in our opinion, because it represents a substantial departure from the status quo for preclinical cancer chemoprevention research of single-agent/single-target approach. The comprehensive research with cutting- edge medicinal chemistry methods (e.g., knockout extract) and systems-biology tools (e.g., iTRAQ proteomics) can help moving herbal remedies toward evidence-based complementary and alternative medicine.
描述(申请人提供):我们的长期目标是从韩国当归(AGN)中开发无毒、低成本和有效的草药药物,用于预防男性前列腺癌的发生和转移。我们已经在临床前模型中显示了AGN乙醇提取物对宿主小鼠的明显的前列腺癌生长抑制和化学预防作用,而没有任何可观察到的毒性。然而,缺乏对活性化学物质和体内分子靶点的机械知识是将预防益处转化为男性的重大障碍。目前应用的目标是在两个独立和互补的前列腺癌模型中产生关于(1)活性化学物质和(2)细胞和分子靶标的机制知识。我们假设,AGN提取物在体内发挥功效:(A)主要通过吡喃香豆素化合物及其代谢物;(B)通过影响关键的细胞过程和分子靶标,可以通过系统生物学方法有效地描绘出来。我们计划通过追求三个特定的目标来验证这些假说:目的1.通过比较纯化的化合物与AGN提取物和吡喃香豆素基因敲除(KO)提取物在免疫缺陷小鼠异种移植模型中抑制人前列腺癌生长和转移的效果,确定吡喃香豆素的化学中介作用。目的2.通过与AGN提取物和KO提取物的比较,验证它们在转基因小鼠前列腺癌(TRAMP)模型化学预防原发癌变中的中介作用。目的3.通过聚焦分析确定体内效应的关键细胞指标和分子生物标记物,包括血管生成、细胞凋亡、细胞增殖和侵袭性,并利用系统生物学方法确定分子靶点,使用前两个目标的合适组织。AIMS 1和2中提出的工作有望严格评估吡喃香豆素和代谢物作为化学介体对AGN提取物抑制前列腺癌发生和转移的作用,并在小鼠模型中建立它们的长期安全性概况。预计这些结果将对AGN草药产品未来的重点研发工作和质量控制产生积极影响。目的3的结果有望确定候选的体内分子靶点和细胞过程。更好地了解模型系统中的活性化学物质及其分子靶标,可以进一步进行机械性研究,并合理规划男性临床翻译。此外,AGN提取物的功效和机制可能也可用于预防其他器官部位的癌症。在我们看来,这项研究具有创新性,因为它代表了对单剂/单靶点方法的临床前癌症化学预防研究现状的实质性偏离。使用尖端药物化学方法(如基因敲除提取物)和系统生物学工具(如iTRAQ蛋白质组学)进行的综合研究有助于将草药疗法推向循证补充和替代医学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUNXUAN LU其他文献
JUNXUAN LU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUNXUAN LU', 18)}}的其他基金
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8504056 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8829786 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
8625728 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
9262164 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM
下一代硒预防前列腺癌
- 批准号:
9063529 - 财政年份:2013
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
9044040 - 财政年份:2012
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8700324 - 财政年份:2012
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8547743 - 财政年份:2012
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8368398 - 财政年份:2012
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
- 批准号:
8867146 - 财政年份:2012
- 资助金额:
$ 13.09万 - 项目类别:
相似国自然基金
ELL在前列腺癌发生中的负性作用机制及其临床意义
- 批准号:81101948
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
miRNA let-7a下调IGF1R抑制前列腺癌细胞雄激素非依赖性生长的作用机制
- 批准号:81071720
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
前列腺癌冷冻消融后HMGB1调节冷冻免疫反应相关机制研究
- 批准号:81001002
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
晚期糖基化终产物受体与视网膜母细胞瘤蛋白在前列腺癌细胞中的相互作用及意义
- 批准号:30700835
- 批准年份:2007
- 资助金额:16.0 万元
- 项目类别:青年科学基金项目
Kallikrein 4(KLK4)受激素调控的机制和对激素非依赖前列腺癌生长影响的实验研究
- 批准号:30571853
- 批准年份:2005
- 资助金额:27.0 万元
- 项目类别:面上项目
相似海外基金
UBR5's mechanisms of action in tumorigenesis and immunoregulation
UBR5在肿瘤发生和免疫调节中的作用机制
- 批准号:
10659844 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Molecular mechanisms driving therapy-induced lineage plasticity
驱动治疗诱导的谱系可塑性的分子机制
- 批准号:
10730635 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms by which histone methyltransferases regulate nuclear receptor activity and response to therapy in hormone-driven tumors.
组蛋白甲基转移酶调节核受体活性和激素驱动肿瘤治疗反应的机制。
- 批准号:
10563751 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
前列腺癌中 ERG 驱动的管腔命运的机制和脆弱性
- 批准号:
10572836 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Elucidating mechanisms of therapy response in BRCA2 mutant prostate cancers
阐明 BRCA2 突变前列腺癌的治疗反应机制
- 批准号:
10678578 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
前列腺癌代谢应激诱导的转录调控机制
- 批准号:
10818087 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Efficacy and Mechanisms of Resistance to Neoadjuvant Intensive Androgen Signaling Inhibition
新辅助强化雄激素信号抑制的疗效和机制
- 批准号:
10628272 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
Dissecting Early Tumor Evolution to Uncover Mechanisms of Tumor Initiation and Drug Resistance
剖析早期肿瘤演化,揭示肿瘤发生和耐药机制
- 批准号:
10607859 - 财政年份:2023
- 资助金额:
$ 13.09万 - 项目类别:
CMA-Basic and Translational Mechanisms of Cancer Initiation of the Urothelium in Veterans Exposed to Carcinogens: Interception of tobacco smoking-related bladder cancer by an epigenetic approach
CMA-暴露于致癌物的退伍军人尿路上皮癌症发生的基本和转化机制:通过表观遗传学方法拦截与吸烟相关的膀胱癌
- 批准号:
10260302 - 财政年份:2022
- 资助金额:
$ 13.09万 - 项目类别:
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
- 批准号:
10418461 - 财政年份:2022
- 资助金额:
$ 13.09万 - 项目类别: